Nonalcoholic fatty liver disease (NAFLD) is associated with risks for developing colorectal adenoma. This study aimed to evaluate the association between advanced fibrosis in NAFLD and the risk for colorectal adenoma.
Introduction
Colorectal cancer (CRC) is the 4th leading cause of cancer-related deaths and the 3rd most commonly diagnosed malignancy worldwide. [1] Although the incidence and mortality rates of CRC are rising in many countries, stabilizing or decreasing mortality rates tend to be seen in certain regions, such as North America, Oceania, most European countries, and Japan in Asia owing to advances in CRC management. [2] Most CRCs arise from colorectal adenoma, which is a precursor lesion of CRC based on the adenoma-carcinoma sequence. [3] Therefore, the early detection and removal of colorectal adenoma through health screening colonoscopy have been recognized as the most effective strategy for reducing the incidence, morbidity, and mortality rates of CRC. [4] The risk factors for CRC include age, family history of CRC, alcohol consumption, smoking, and increased red meat consumption. [5] Metabolic syndrome has also recently determined as a potential risk factor for the development of CRC. In several previous studies, the factors for metabolic syndrome, including obesity, dyslipidemia, impaired glucose tolerance, and insulin resistance, could be associated with the development and carcinogenesis of colorectal adenomas. [6, 7] Nonalcoholic fatty liver disease (NAFLD) is defined as the accumulation of fat within the liver and is detected on imaging or histology; its causes exclude excessive alcohol consumption, chronic viral hepatitis, steatogenic medication, and genetic disorder. [8] NAFLD is a major rising cause of liver disease, which is now regarded as a liver manifestation of metabolic syndrome. [9, 10] NAFLD comprises a wide spectrum of liver damage, from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis, which is recognized as a cause of liver failure and hepatocellular carcinoma. [11] Recently, several studies have shown that the carcinogenic effect of NAFLD was not limited to the liver, but also affected extra-hepatic neoplasm, particularly colorectal neoplasm, which was associated with metabolic risk factors, such as insulin resistance and obesity. [12] However, studies on the risk of colorectal neoplasm according to the severity of NAFLD are still lacking. Owing to the invasiveness and high costs of liver biopsy, risk stratification is difficult in patients with NAFLD. To evaluate liver fibrosis noninvasively, several scoring systems have been introduced. [13, 14] In this study, we stratified the severity of NAFLD in subjects who underwent a health screening program using noninvasive score models. This study aimed to evaluate the association between colorectal adenoma and presence of NAFLD and advanced fibrosis.
Methods

Study subjects and design
We reviewed the data of 40,952 adults aged over 19 years who underwent a health screening program at Yeungnam University Hospital in South Korea from September 2009 to June 2017. To evaluate the association with liver fibrosis and colorectal adenoma in subjects with NAFLD, we included 9387 subjects who underwent 1st-time screening colonoscopy and abdominal ultrasound on the same day during the study period. We then excluded 3055 subjects who met any of the following exclusion criteria: missing values (n = 1321); incomplete colonoscopy owing to poor bowel preparation (n = 115); previous history of any cancer (n = 14); previous history of inflammatory bowel diseases, such as ulcerative colitis or Crohn disease (n = 4); CRC detected on colonoscopy during the study period (n = 18, Supplementary Table 1 , http://links.lww.com/MD/C791); secondary causes for steatosis (n = 1572); and liver cirrhosis on abdominal ultrasonography (n = 11). Finally, 6332 subjects were included (Supplementary Figure 1 , http://links.lww.com/MD/ C791). This study was approved by the Institutional Review Board of our Hospital.
Clinical data and laboratory evaluation
During the health screening program, the height, weight, waist circumference, and sitting blood pressure (BP) were measured by well-trained nurses. Data on age, sex, smoking status, alcohol consumption, medical history, and medication use were collected using a self-administered questionnaire. The subjects' smoking status was categorized into: never, formerly, and currently. Alcohol consumption was calculated using the number of drinks consumed multiplied by the frequency. Blood was collected following at least 10 hours of fasting and laboratory evaluation for parameters including complete blood count, blood chemistry, glucose level, and lipid profile was performed by trained staff. Body mass index (BMI) was calculated by dividing the weight (kg) by the height squared (m 2 ), and obesity was defined as a BMI ≥25 kg/m 2 according to the criteria for the Asia-Pacific region. Hypertension was defined as a systolic BP ≥140 mm Hg or a diastolic BP ≥90 mm Hg or with a history of the disease/medication use. Diabetes mellitus (DM) was defined as a fasting glucose level ≥126 mg/dL or HbA1c level ≥6.5% or with a history of the disease/medication use. Hyperlipidemia was defined as a serum triglyceride level ≥150 mg/ dL or a serum cholesterol level ≥200 mg/dL or with a history of the disease/medication use. Metabolic syndrome was defined in accordance with the International Diabetes Federation criteria as central obesity (waist circumference ≥90 cm in men and ≥80 cm in women based on ethnic-specific values) plus 2 of the following 4 factors: increased triglyceride level (≥150 mg/dL) or specific treatment for this lipid abnormality; reduced high-density lipoprotein cholesterol level (<40 mg/dL in men and < 50 mg/dL in women) or on specific treatment for this lipid abnormality; systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or treatment of previously diagnosed hypertension; and increased fasting plasma glucose level (≥100 mg/dL) or previous diagnosis of type 2 DM.
Colonoscopy procedure and detection of colorectal adenoma
All colonoscopies were performed by well-trained board-certified gastroenterologists using a conventional colonoscope (CV-160 Evis EXTRA and CV-180 Evis EXTRA II; Olympus, Tokyo, Japan) after bowel preparation with 4 L of polyethylene glycol solutions. All subjects were sedated using midazolam and/or propofol. The degree of sedation was minimal to moderate as defined by the American Society of Anesthesiologists. A complete examination was defined in accordance with the following criteria: reached the cecum, and the appendiceal orifice could be identified; the bowel preparation was adequate with no more than adherent feces or small amount of feces or fluid not interfering with the examination; and the colonoscopy was performed for at least 6 minutes. Abnormal polypoid lesions were biopsied or resected endoscopically with records of the location, size, appearance, and numbers. All specimens of colorectal neoplasia were evaluated and classified in accordance with the World Health Organization standards by board-certified pathologists. Advanced adenoma was defined as an adenoma with a ≥10-mm diameter, high-grade dysplasia, or >25% villous component. Multiple adenomas were defined as the presence of three or more adenomas, regardless of the location.
Diagnosis of NAFLD and staging of liver fibrosis
An abdominal ultrasound was performed to assess the presence of fatty infiltration of the liver using EPIQ 5 and EPIQ 7 (Philips Healthcare, Amsterdam, Netherlands) by experienced ultrasonographists on the same day of the colonoscopy procedure. The liver of each subject was examined for size, echogenicity, contour, structure and posterior beam attenuation, and fatty infiltration, which was diagnosed in accordance with the standard criteria, including liver parenchymal brightness, liverto-kidney contrast, and deep beam attenuation. NAFLD was diagnosed in accordance with the following criteria: evidence of fatty infiltration of the liver on abdominal ultrasound, alcohol consumption <210 g/week for men and <140 g/week for women, and absence of secondary causes of hepatic fat accumulation, such as viral hepatitis (hepatitis B virus/hepatitis C virus [HCV]), autoimmune disease, use of steatogenic medication, or hereditary disorders. [8] NAFLD was further stratified on the basis of the presence of advanced fibrosis using noninvasive methods, that is, complex score models, including the NAFLD fibrosis score (NFS) and fibrosis-4 (Fib-4) index; and simple score models, including the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and BMI, AST-to-alanine aminotransferase (ALT) ratio, Diabetes (BARD) score; each score formula is shown in Supplementary Table 2, http://links.lww.com/MD/C791. The NFS has dual predictive cutoff values: low cutoff value of À1.455 for excluding advanced fibrosis and high cutoff value of 0.676 for diagnosing advanced fibrosis in patients with NAFLD. [15] The Fib-4 index also has dual predictive cutoff values: low cutoff value of 1.30 for excluding advanced fibrosis and high cutoff value of 2.67 for advanced fibrosis in patients with NAFLD. [16] An APRI >1 was a significant predictor of advanced fibrosis in patients with NAFLD. [17] A BARD score of 2 to 4 points was 98:6 Medicine considered to indicate F3 or F4 stage of fibrosis. [18] For the subjects with NAFLD in this study, an NFS >0.676, a Fib-4 index >2.67, an APRI >1, and a BARD score ≥2 were considered to indicate advanced fibrosis in NAFLD; conversely, an NFS <À1.455, a Fib-4 index <1.30, an APRI 1, and a BARD score <2 were considered to indicate nonadvanced fibrosis in NAFLD. The NFS range of -1.455 to 0.676 and Fib-4 index range of 1.30 to 2.67 were considered indeterminate scores and indicate an unclear presence of advanced fibrosis in NAFLD.
Statistical analysis
Continuous and categorical variables were expressed as mean ± standard deviation and n (%), respectively. Statistical analysis was performed using SPSS version 23.0 (IBM, Armonk, NY), and the level of statistical significance was set at P < .05. The characteristics of the study subjects were analyzed based on the NAFLD status using Student t test for continuous variables and the Chi-squared test for categorical variables. Logistic regression analysis was used to determine the risk factors associated with colorectal adenoma in the study subjects. The odds ratio (OR) was considered to be statistically significant if the 95% confidence interval (CI) did not include 1.0. The variables used to calculate the complex or simple score models were not included in each logistic regression analysis.
Results
Baseline characteristics of the study subjects
Among the 6332 subjects enrolled in this study, 2395 (37.8%) had NAFLD. The baseline characteristics are shown in Table 1 . The subjects with NAFLD were older (50.34 ± 10.33 vs 48.70 ± 10.94, P < .001) and predominantly men (71.3% vs 51.0%, Table 1 Baseline characteristics of the study subjects with and without NAFLD.
Variables
Non-NAFLD n = 3937 (62.2%) NAFLD n = 2395 (37.8%) P ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BP = blood pressure, CRP = C-reactive protein, GGT = gamma-glutamyl transpeptidase, HDL = high-density lipoprotein, NAFLD = nonalcoholic fatty liver disease, WBC = white blood cell.
Kim et al. Medicine (2019) 98:6 www.md-journal.com P < .001), had a higher BMI (25.54 ± 2.85 vs 22.74 ± 2.61; P < .001), and were predominantly current smokers (24.0% vs 15.8%, P < .001) than those without NAFLD. The prevalence of hypertension (25.1% vs 14.2%, P < .001), DM (14.9% vs 4.7%, P < .001), hyperlipidemia (71.4% vs 52.1%, P < .001), and metabolic syndrome (16.7% vs 3.7%, P < .001) was higher in the subjects with NAFLD. In the liver function test, the levels of serum AST, ALT, and gamma-glutamyl transpeptidase were also significantly higher in the subjects with NAFLD.
Association between NAFLD and risk of colorectal adenoma in the study subjects
During the study period, colorectal adenoma was found in 1735 (27.4%) subjects on 1st-time colonoscopy. The subjects with NAFLD had a higher prevalence of colorectal adenoma (33.3% vs 23.8%, P < .001) than the subjects without NAFLD. Moreover, the prevalence of advanced adenoma (5.3% vs 2.4%, P < .001) and multiple adenomas (5.8% vs 3.0%, P < .001) was also higher in the subjects with NAFLD (Table 1) . After adjusting for confounding factors, including age, sex, obesity, smoking, hypertension, DM, hyperlipidemia, and metabolic syndrome, the subjects with NAFLD had a significantly higher risk for colorectal adenoma (OR, 1.15; 95% CI, 1.02-1.30; P = .027). Further, NAFLD was also an independent risk factor for advanced adenoma (OR, 1.50; 95% CI, 1.12-2.01; P = .006) and multiple adenomas (OR, 1.32; 95% CI, 1.01-1.73; P = .006) ( Table 2 ).
Association between advanced liver fibrosis and risk of colorectal adenoma in NAFLD
The prevalence of colorectal adenoma was significantly higher in the subjects with NAFLD with advanced fibrosis than in those with NAFLD without advanced fibrosis, which was stratified using the NFS and Fib-4 index (Supplementary Table 3 , http:// links.lww.com/MD/C791). The association between advanced fibrosis in NAFLD and risk of colorectal adenoma is shown in Table 3 . Advanced fibrosis, which was stratified using the NFS and Fib-4 index while adjusting for confounding factors, was associated with significantly higher risks of colorectal adenoma in the subjects with NAFLD. However, there was no association with the risk for colorectal adenoma and advanced fibrosis when stratified using the APRI and BARD score.
Association between advanced liver fibrosis and risk of advanced adenoma and multiple adenomas in NAFLD
The prevalence of advanced adenoma and multiple adenomas was significantly higher in the subjects with NAFLD with advanced fibrosis than in those with NAFLD without advanced fibrosis, which was stratified using the NFS, Fib-4 index, and Table 4 , http://links.lww.com/MD/C791). After adjusting for confounding factors, NAFLD with advanced fibrosis, which was stratified using the NFS, Fib-4 index, and APRI, was an independent risk factor for advanced adenoma (Table 4 ) and multiple adenomas (Table 5) .
Association between advanced liver fibrosis and risk of colorectal adenoma in the study subjects
The risk of colorectal adenoma, advanced adenoma, and multiple adenomas in the subjects with NAFLD and advanced fibrosis was more robust than that in the subjects without Table 3 Univariate and multivariate logistic regression analyses of the risk of colorectal adenoma according to the parameters of NAFLD severity. For the NFS, the multivariable model was not adjusted for age, BMI, and DM. For the Fib-4 index, the multivariable model was not adjusted for age. For the BARD score, the multivariable model was not adjusted for BMI and DM. APRI = aspartate aminotransferase (AST)-to-platelet ratio, BARD = BMI = AST-to-alanine aminotransferase ratio = diabetes, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, Fib-4 = fibrosis-4, NAFLD = nonalcoholic fatty liver disease, NFS = NAFLD fibrosis score, OR = odds ratio. * An NFS of <À1.455, a Fib-4 index of <1.30, an APRI of <1, and a BARD score of <2 were considered to indicate the absence of advanced fibrosis in NAFLD. † P < .05 and OR > 1.2 was considered clinically significant. ‡ An NFS of > 0.675, a Fib-4 index of >2.67, an APRI of ≥1, and a BARD score of ≥2 were considered to indicate the presence of advanced fibrosis in NAFLD.
Table 4
Univariate and multivariate logistic regression analyses of the risk of advanced adenoma according to the parameters of NAFLD severity in the subjects with NAFLD. For the NFS, the multivariable model was not adjusted for age, BMI, and DM. For the Fib-4 index, the multivariable model was not adjusted for age. For the BARD score, the multivariable model was not adjusted for BMI and DM. APRI = aspartate aminotransferase (AST)-to-platelet ratio, BARD = BMI = AST-to-alanine aminotransferase ratio = diabetes, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, Fib-4 = fibrosis-4, NAFLD = nonalcoholic fatty liver disease, NFS = NAFLD fibrosis score, OR = odds ratio. * An NFS of <À1.455, a Fib-4 index of <1.30, an APRI of <1, and a BARD score of <2 were considered to indicate the absence of advanced fibrosis in NAFLD. † P < .05 and OR > 1.2 was considered clinically significant. ‡ An NFS of >0.675, a Fib-4 index of >2.67, an APRI of ≥1, and a BARD score of ≥2 were considered to indicate the presence of advanced fibrosis in NAFLD. (2019) 98:6 www.md-journal.com NAFLD in all noninvasive score models (Table 6 ). However, the risk of colorectal adenoma, advanced adenoma, and multiple adenomas in those with NAFLD without advanced fibrosis was not significantly different from those without NAFLD.
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Discussion
In this study, the presence of NAFLD was associated with the risk of colorectal adenoma, advanced adenoma, and multiple adenomas in asymptomatic adults who underwent 1st-time screening colonoscopy. After adjusting for demographic and Table 5 Univariate and multivariate logistic regression analyses of the risk of multiple adenomas according to the parameters of NAFLD severity in the subjects with NAFLD. For the NFS, the multivariable model was not adjusted for age, BMI, and DM. For the Fib-4 index, the multivariable model was not adjusted for age. For the BARD score, the multivariable model was not adjusted for BMI and DM. APRI = aspartate aminotransferase (AST)-to-platelet ratio, BARD = BMI = AST-to-alanine aminotransferase ratio = diabetes, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, Fib-4 = fibrosis-4, NAFLD = nonalcoholic fatty liver disease, NFS = NAFLD fibrosis score, OR = odds ratio. * An NFS of <À1.455, a Fib-4 index of <1.30, an APRI of <1, and a BARD score of <2 were considered to indicate the absence of advanced fibrosis in NAFLD. † P < .05 and OR > 1.2 was considered clinically significant. ‡ An NFS of >0.675, a Fib-4 index of >2.67, an APRI of ≥1, and a BARD score of ≥2 were considered to indicate the presence of advanced fibrosis in NAFLD. Table 6 Risk of colorectal adenoma according to the parameters of NAFLD severity in the study population. For the NFS, the multivariable model was not adjusted for age, BMI, and DM. For the Fib-4 index, the multivariable model was not adjusted for age. For the BARD score, the multivariable model was not adjusted for BMI and DM. APRI = aspartate aminotransferase (AST)-to-platelet ratio, BARD = BMI = AST-to-alanine aminotransferase ratio = diabetes, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, Fib-4 = fibrosis-4, NAFLD = nonalcoholic fatty liver disease, NFS = NAFLD fibrosis score, OR = odds ratio.
metabolic risk factors, which are currently considered to be risk factors for colorectal neoplasm, our study showed that not only age, male sex, and metabolic syndrome but also NAFLD was a significant independent risk factor for colorectal adenoma, advanced adenoma, and multiple adenomas. Based on these results, we further investigated the risk of colorectal adenoma according to the staging of fibrosis in NAFLD, which was closely associated with a higher risk of colorectal adenoma. The relationship between ultrasound-diagnosed NAFLD and colorectal adenoma has been already reported in previous population-based studies. [19] [20] [21] In these studies, NAFLD was an independent risk factor for colorectal neoplasia. Though our results are similar with ones from these studies, NAFLD was an independent risk factor for colorectal adenoma without clinical significance owing to relatively low OR (Table 2) . [22] In a crosssectional study of 181 community subjects aged 40 to 70 years and 191 subjects with biopsy-proven NAFLD, NAFLD was associated with a higher prevalence of colorectal adenoma and advanced adenoma. [20] This study showed that nonalcoholic steatohepatitis (NASH) was associated with a high prevalence of colorectal adenoma and advanced adenoma but not NAFLD without NASH among subjects with biopsy-proven NAFLD. Although liver biopsy is the gold standard for assessing the severity of NAFLD, it can be performed only in a limited number of patients with NAFLD, which also causes a potential selection bias. Moreover, liver biopsy has potential risks for sampling errors, intra-and inter-observer variabilities, and complications such as pain, bleeding, and even death. [23] Therefore, many previous studies have used various noninvasive score models, which are applicable to common patients with NAFLD, including the APRI, BARD score, NFS, Fib-4 index, Hepascore, Enhanced Liver Fibrosis test score, FibroTest score, and FibroMeter score. [13, 15, 18, 24, 25] Most of these score models stratified patients with NAFLD according to the presence of advanced fibrosis using indirect serum markers and demographic features. Among these models, we used 4 score models, including the NFS, Fib-4 index, APRI, and BARD score. The scoring system of these 4 models consists of clinical and laboratory data, including age, obesity, DM, transaminase level, platelet count, and albumin level (Supplementary Table 5 , http://links.lww.com/MD/C791), which are routinely measured and readily available through a general health screening program.
The NFS includes 6 variables, including age, hyperglycemia, BMI, platelet count, AST-to-ALT ratio, and albumin level, which are independent risk factors for advanced fibrosis. It has a dual cutoff value; a low cutoff value of À1.455 for excluding advanced fibrosis with a 93% negative predictive value and a high cutoff value of 0.676 for diagnosing advanced fibrosis with a 90% positive predictive value. [15] The Fib-4 index was originally developed for predicting advanced fibrosis in patients infected with HIV-HCV using age and routine tests, including the AST and ALT levels and platelet count. [24] The Fib-4 index has also showed a superiority to other noninvasive markers, such as the NFS, Göteborg University Cirrhosis index, AST-to-ALT ratio, APRI, and BARD score, in diagnosing advanced fibrosis in patients with NAFLD as well as in HIV-HCV coinfected patients in several studies. [16, 26] It also has a dual cutoff value; the high cutoff value of 2.67 predicts the diagnosis of advanced fibrosis with an 80% positive predictive value, and the low cutoff value of 1.30 predicts the exclusion of advanced fibrosis with a 90% negative predictive value. The APRI, which was one of the simple models, consists of the AST and ALT levels and platelet count, which could predict significant fibrosis in patients with chronic hepatitis C. [25] A recent study has shown that an APRI above 1 was the most significant predictor for advanced fibrosis in NAFLD among 358 patients with biopsy-proven NAFLD. [17] The other simple model, the BARD score, consists of the weighted sum of BMI, AST-to-ALT ratio, and DM to predict significant fibrosis in patients with NAFLD. [18] Its cutoff value of 2 predicts advanced fibrosis with a 43% positive predictive value and 96% negative predictive value. However, it has limitations of a relatively high false positivity owing to the overestimation of BMI and DM and has the lowest predictive values for predicting significant fibrosis among the APRI, Fib-4 index, Hepascore, and FibroTest score. [27] In our study, the risk of colorectal adenoma was significantly higher in the subjects with NAFLD and advanced fibrosis than in those with NAFLD without advanced fibrosis; this result was more robust when NAFLD was stratified using the complex score models, including the NFS and Fib-4 index. This result is supported by the findings of several studies that compared accuracy of predicting advanced fibrosis of NAFLD between complex score models and simple score models. In a multicenter study of 242 patients with biopsy-proven NAFLD, the complex models, including the Hepascore, FibroTest score, and Fib-4 index, were more accurate in the prediction of NAFLD with advanced fibrosis than the simple models, including the APRI and BARD score. [27] In a meta-analysis on the diagnostic accuracy of noninvasive tests for liver disease severity, the FibroTest score, Enhanced Liver Fibrosis test score, and NFS had higher diagnostic accuracies than the APRI and BARD score. [28] There have been several observational and experimental studies conducted on the mechanisms that can support the finding that NAFLD affects the development of colorectal neoplasm. These studies have shown that chronic inflammation and insulin resistance could induce the development of colorectal neoplasm. [29] It is known that NAFLD is also related to the proinflammatory state and insulin resistance, and these affect each other. [30] Intrahepatic lipid accumulation induces hepatic cells to produce proinflammatory cytokines, including tumor necrosis factor-a (TNF-a), interleukin (IL)-6, and IL-8, which play a key role in angiogenesis, promotion of cellular proliferation, and inhibition of apoptosis in the development of colorectal neoplasm. [31] [32] [33] Insulin resistance in the hepatic and adipose tissues induces hyperinsulinemia and elevated insulin-like growth factor (IGF), which may promote the development of colorectal neoplasm through proliferative and anti-apoptotic effects. [34] Adiponectin, one of the adipokines with anti-inflammatory effects, is also an important cytokine involved in the association between NAFLD and colorectal neoplasm. [34, 35] Several studies have shown that adiponectin directly inhibits TNF-a and that low levels of adiponectin increase insulin and IGF-1 levels. [36, 37] The expression of adiponectin was reduced in patients with NAFLD, which was associated with a high risk of colorectal adenoma. [34, 38] A positive correlation was observed between the degree of liver fibrosis and level of proinflammatory cytokines, including TNF-a and IL-6. Further, NASH yields significantly lower levels of adiponectin. [38] Moreover, there was a significant association between insulin resistance and liver fibrosis. [39] These findings demonstrate the potential risk of colorectal adenoma in patients with NAFLD and advanced fibrosis.
Our study has some limitations. First, this study was restricted to colorectal adenoma, except for CRC, because CRC was diagnosed in only 18 subjects during the study period, and its prevalence did not show any difference according to the presence of NAFLD. We think that further large-scale studies are needed to evaluate the relationship between CRC and NAFLD with and www.md-journal.com without fibrosis. Second, this cross-sectional study was conducted during a health screening program in a single center. The subjects enrolled in this study visited the hospital for the health screening program and might not be representative of the general population with an average risk. Therefore, this study could not infer any causality between NAFLD and colorectal adenoma. Additionally, South Koreans have different colorectal adenoma characteristics, such as prevalence and location, compared with Westerners. [40] To achieve generalizability of the findings of this study, further studies involving multiple regions or ethnicities are needed. However, the findings of this study are meaningful owing to the relatively large number of subjects than in other studies. Moreover, most results from various models for the prediction of fibrosis are constant in patients with NAFLD.
Our findings demonstrated that NAFLD is independently associated with a high risk of colorectal adenoma as well as advanced adenoma and multiple adenomas. Furthermore, the presence of advanced fibrosis significantly increased the risk for colorectal adenoma, advanced adenoma, and multiple adenomas compared with the absence of advanced fibrosis. Further studies are needed to evaluate the intervals of colonoscopy surveillance after 1st-time colonoscopy in patients with NAFLD with and without fibrosis. In conclusion, when patients with NAFLD are considered for colonoscopy screening, clinicians should be aware that patients with fibrosis may have a higher risk for colorectal adenoma than those without fibrosis.
